Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L.

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

December 6, 2024

Study Completion Date

December 6, 2024

Conditions
Hematologic MalignanciesThrombopenia
Interventions
OTHER

Blood sample

A blood sample will be taken from all patients included in the study. This blood sampling is an added act of the study. It will be performed as soon as possible after inclusion in the study. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.

Trial Locations (1)

Unknown

Centre Hospitalier Annecy Genevois, Annecy

All Listed Sponsors
lead

Centre Hospitalier Annecy Genevois

OTHER

NCT06455553 - Interpretability of the Quantra® Viscoelastic Test in Patients With Haematological Malignancies With Profound Thrombocytopenia Below 50x10 G/L. | Biotech Hunter | Biotech Hunter